AngioDynamics Added to the Russell 3000 Index and the New Russell Microcap Index

AngioDynamics Added to the Russell 3000 Index and the New Russell Microcap Index

QUEENSBURY, N.Y.--(BUSINESS WIRE)--June 27, 2005--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that its common stock has been added to the Russell 3000^® Index and the new Russell Microcap^™ Index on June 24, 2005, following Russell Investment Group's reconstitution of its family of U.S. indices.

The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization. As of the latest reconstitution, the average market capitalization was approximately $4.4 billion; the median market capitalization was approximately $822.4 million. The index had a total market capitalization range of approximately $317.8 billion to $175.8 million.

The new Russell Microcap Index is designed to offer managers and other investors a comprehensive, unbiased barometer to compare their performance against the genuine microcap marketplace of stocks. It will be composed of the smallest 1,000 securities in the small-cap Russell 2000 Index plus the next 1,000 companies, based on a ranking of all U.S. equities by market capitalization. The index will exclude less-regulated OTC Bulletin Board securities or Pink Sheet stocks priced under $1.

"Inclusion on these lists is a strong testament to the progress we have made in the capital markets since our May 2004 initial public offering," said Eamonn P. Hobbs, CEO of AngioDynamics. "We are pleased that AngioDynamics stock will have this additional avenue of recognition within the investment community."

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. The Company designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. Its diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended February 26, 2005, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.

    CONTACT: AngioDynamics, Inc.
             Joe Gerardi, 800-772-6446, ext. 115
             www.angiodynamics.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates, Inc.
             Kim Sutton Golodetz (kgolodetz@lhai.com)
             212-838-3777
             Bruce Voss (bvoss@lhai.com)
             310-691-7100

    SOURCE: AngioDynamics, Inc.